Jubilant Pharmova Limited
JUBLPHARMA · General/Diversified · NSE
₹907
Current Market Price
Fair Value (DCF)
₹753
Margin of Safety
-17.0%
Updated just now
YieldIQ Score
48/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
39%
ROE
13.4%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.14 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
11.3%
Return on capital employed
EV / EBITDA
13.6×
Enterprise multiple
Debt / EBITDA
2.3×
Leverage vs earnings
Interest Coverage
5.4×
EBIT covers interest
Current Ratio
1.65×
Short-term liquidity
Asset Turnover
0.61×
Revenue per ₹ of assets
Revenue CAGR (3Y)
7.1%
3-year revenue growth
Revenue CAGR (5Y)
4.8%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹907
Bear case
₹416.1
MoS -118.0%
Base case
₹752.52
MoS -20.5%
Bull case
₹1,049.69
MoS +13.6%
Ratio Trends
JUBLPHARMA · last 8 annual periods
ROE
13.5%
ROCE
17.5%
Operating Margin
—
Debt / Equity
0.44×
PE
14.9×
EV / EBITDA
4.9×
Historical Financials
JUBLPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹6099 Cr | ₹6059 Cr | ₹6282 Cr | ₹6703 Cr | ₹7192 Cr | +4.2% |
| EBITDA | — | ₹1150 Cr | ₹750 Cr | ₹809 Cr | ₹1570 Cr | +8.1% |
| EBIT | ₹1044 Cr | ₹786 Cr | ₹204 Cr | ₹419 Cr | — | -20.4% |
| PAT | ₹836 Cr | ₹413 Cr | ₹-64.9 Cr | ₹72.7 Cr | ₹839 Cr | +0.1% |
| EPS (diluted) | ₹36.05 | ₹26.00 | ₹-3.83 | ₹4.86 | — | -39.4% |
| CFO | ₹1482 Cr | ₹838 Cr | ₹661 Cr | ₹971 Cr | ₹1072 Cr | -7.8% |
| CapEx | — | — | — | — | ₹-1116 Cr | — |
| FCF | — | — | — | — | ₹-43.5 Cr | — |
| Total Assets | — | ₹9991 Cr | ₹11.2K Cr | ₹11.5K Cr | ₹12.8K Cr | +6.3% |
| Total Debt | — | — | ₹300 Cr | ₹247 Cr | ₹2731 Cr | +73.7% |
| Shareholders' Equity | — | — | ₹5399 Cr | ₹5434 Cr | ₹6239 Cr | +3.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
JUBLPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| COHANCE COHANCE | — | — | Pending | 14.6% | — |
| APLLTD APLLTD | — | — | Pending | 11.2% | — |
| CAPLIPOINT CAPLIPOINT | — | — | Pending | 18.6% | — |
| ALIVUS ALIVUS | — | — | Pending | 17.2% | — |
| GRANULES GRANULES | — | — | Pending | 13.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹25.00/sh
Last payout
2025-07-25
₹5.00
Peak payout
₹5.00
Trailing yield
0.55%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Jubilant Pharmova Limited (JUBLPHARMA.NS) trades at 907.00 vs a model fair value of 752.52, a gap of -17.0%. Piotroski F-score: 5/9. Moat...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of JUBLPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for JUBLPHARMA →
Compare
Head-to-head with peers
Compare JUBLPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse JUBLPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.